Ivabradine in patients with heart failure: a systematic literature review

References

• Savarese G, Becher PM, Lund LH, et al. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res. 2023 Feb 12;118(17):3272–14. doi: 10.1093/cvr/cvac013
   PubMed Web of Science ®Google Scholar
• McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021 [2021 Sep 21];42(36):3599–3726. doi: 10.1093/eurheartj/ehab368
   PubMed Web of Science ®Google Scholar
• McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019 Nov 21;381(21):1995–2008. doi: 10.1056/NEJMoa1911303
   PubMed Web of Science ®Google Scholar
• Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020 Oct 8;383(15):1413–1424. doi: 10.1056/NEJMoa2022190
   PubMed Web of Science ®Google Scholar
• Ponikowski P, Voors AA, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the heart failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129–2200. doi: 10.1093/eurheartj/ehw128
   PubMed Web of Science ®Google Scholar
• Anantha Narayanan M, Reddy YN, Baskaran J, et al. Ivabradine in the treatment of systolic heart failure: a systematic review and meta-analysis. World J Cardiol. 2017 Feb 26;9(2):182–190. doi: 10.4330/wjc.v9.i2.182
   PubMedGoogle Scholar
• Böhm M, Swedberg K, Komajda M, et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet. 2010 Sep 11;376(9744):886–894. doi: 10.1016/S0140-6736(10)61259-7
   PubMed Web of Science ®Google Scholar
• Les Laboratoires Servier. Procoralan: European Medicines Agency; 2021 [updated Nov 2005;12 April 2023]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/procoralan
   Google Scholar
• Koruth JS, Lala A, Pinney S, et al. The clinical use of ivabradine. J Am Coll Cardiol. 2017 Oct 3;70(14):1777–1784. doi: 10.1016/j.jacc.2017.08.038
   PubMed Web of Science ®Google Scholar
• Heidenreich PA, Bozkurt B, Aguilar D, et al. AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American heart Association Joint Committee on clinical practice guidelines. Circulation. 2022 [2022 May 3];145(18):e895–e1032.
   PubMed Web of Science ®Google Scholar
• Böhm M, Borer J, Ford I, et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clin Res Cardiol. 2013 Jan;102(1):11–22. doi: 10.1007/s00392-012-0467-8
   PubMed Web of Science ®Google Scholar
• Higgins JT, Chandler J, Cumpston M, et al. editors. Cochrane Handbook for Systematic Reviews of Interventions. 2nd. Chichester (UK): John Wiley & Sons; 2019. doi: 10.1002/9781119536604
   Google Scholar
• CRD. Systematic reviews: cRD’s guidance for undertaking reviews in health care. York: Centre for Reviews and Dissemination, University of York; 2009.
   Google Scholar
• Sterne JS, Page MJ, Elbers RG, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. doi: 10.1136/bmj.l4898
   PubMed Web of Science ®Google Scholar
• Julian Higgins DA, Curtin F, Tianjing L, et al. Additional considerations for cross-over trials. Odense, Denmark: Cochrane Bias Methods Group; 2021 [cited 2021]. Available from: https://drive.google.com/file/d/11LFgCuDpWk5-BvBNbHtNzbJv5-qVpTWb
   Google Scholar
• Wells G, Shea B, O’Connell J. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses. 2014.
   Google Scholar
• Abdel-Salam Z, Rayan M, Saleh A, et al. I(f) current inhibitor ivabradine in patients with idiopathic dilated cardiomyopathy: impact on the exercise tolerance and quality of life. Cardiol J. 2015;22(2):227–232. doi: 10.5603/CJ.a2014.0057
   PubMed Web of Science ®Google Scholar
• Abdullaev A, Mammaev S, Anatova A, et al. The effect of ivabradine as part of standard therapy on vascular endothelial function and cardiac electrical instability in patients with post-infarction cardiosclerosis and heart failure. Russ J Cardiol. 2020 10 02;25(1):52–58. doi: 10.15829/1560-4071-2020-1-3592
   Google Scholar
• Volterrani M, Cice G, Caminiti G, et al. Effect of Carvedilol, Ivabradine or their combination on exercise capacity in patients with heart failure (the CARVIVA HF trial). Int J Cardiol. 2011 Sep 1;151(2):218–224. doi: 10.1016/j.ijcard.2011.06.098
   PubMed Web of Science ®Google Scholar
• Lofrano-Alves MS, Issa VS, Biselli B, et al. Control of sinus tachycardia as an additional therapy in patients with decompensated heart failure (CONSTATHE-DHF): a randomized, double-blind, placebo-controlled trial. J Heart Lung Transplant. 2016 Oct;35(10):1260–1264. doi: 10.1016/j.healun.2016.06.005
   PubMed Web of Science ®Google Scholar
• Cavusoglu Y, Mert U, Nadir A, et al. Ivabradine treatment prevents dobutamine-induced increase in heart rate in patients with acute decompensated heart failure. J Cardiovasc Med (Hagerstown). 2015 Sep;16(9):603–609. doi: 10.2459/JCM.0000000000000033
   PubMed Web of Science ®Google Scholar
• Hidalgo FJ, Anguita M, Castillo JC, et al. Effect of early treatment with ivabradine combined with beta-blockers versus beta-blockers alone in patients hospitalised with heart failure and reduced left ventricular ejection fraction (ETHIC-AHF): a randomised study. Int J Cardiol. 2016 Aug 15;217:7–11. doi: 10.1016/j.ijcard.2016.04.136
   PubMed Web of Science ®Google Scholar
• Tsutsui H, Momomura S, Yamashina A, et al. Heart rate control with if inhibitor, ivabradine, in Japanese patients with chronic heart failure: a randomized, double-blind, placebo-controlled phase II study. Circ J. 2016;80(3):668–676. doi: 10.1253/circj.CJ-15-1112
   PubMed Web of Science ®Google Scholar
• Kanorskiĭ SG, Tregubov VG, Pokrovskiĭ VM. Alternative therapy with ivabradine in patients with functional class III chronic heart failure [in Russian]. Kardiologiia. 2011;51(8):39–44.
   PubMed Web of Science ®Google Scholar
• Babushkina GV, Shaikhlislamova GI. Ivabradine for treatment of heart failure with preserved ejection fraction [in Russian]. Kardiologiia. 2020;60(10):33–37. doi: 10.18087/cardio.2020.10.n1324
   PubMed Web of Science ®Google Scholar
• Mansour S, Youssef A, Rayan M, et al. Efficacy of ivabradine in idiopathic dilated cardiomyopathy patients with chronic heart failure. Egypt Heart J. 2011 01 06;63(2):79–85. doi: 10.1016/j.ehj.2011.09.001
   Google Scholar
• Ordu S, Yildiz BS, Alihanoglu YI, et al. Effects of ivabradine therapy on heart failure biomarkers. Cardiol J. 2015;22(5):501–509. doi: 10.5603/CJ.a2015.0012
   PubMed Web of Science ®Google Scholar
• Othman KMS, Mostafa MAR, Yosef AE, et al. Safety and efficacy of off-label use of ivabradine in patients with acute heart failure. J Saudi Heart Assoc. 2019 Oct;31(4):179–187. doi: 10.1016/j.jsha.2019.05.006
   PubMed Web of Science ®Google Scholar
• Potapenko AV, Abdulazizov O, Diachuk LI, et al. Efficacy of ivabradin in combined treatment of patients with postinfarction systolic chronic cardiac failure [in Russian]. Ter Arkh. 2011;83(12):19–26.
   PubMed Web of Science ®Google Scholar
• Mentz RJ, DeVore AD, Tasissa G, et al. PredischaRge initiation of ivabradine in the ManagEment of heart failure: results of the PRIME-HF trial. Am Heart J. 2020 May;223:98–105.
   PubMed Web of Science ®Google Scholar
• NCT. Predischarge initiation of ivabradine in the management of heart failure (PRIME-HF). NCT02827500: Clinicaltrials.gov; 2018 [12 April 2023]. Available from: https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01584213/full
   Google Scholar
• Raja DC, Kapoor A, Sinha A, et al. Heart rate manipulation in dilated cardiomyopathy: assessing the role of Ivabradine. Indian Heart J. 2018 Mar-Apr;70(2):246–251. doi: 10.1016/j.ihj.2017.08.009
   PubMedGoogle Scholar
• Sallam M, Al-Saadi T, Alshekaili L, et al. Impact of ivabradine on health-related quality of life of patients with ischaemic chronic heart failure. Curr Vasc Pharmacol. 2016;14(5):481–486. doi: 10.2174/1570161114666160505143003
   PubMed Web of Science ®Google Scholar
• Sarullo FM, Fazio G, Puccio D, et al. Impact of ’‘off-label’’ use of ivabradine on exercise capacity, gas exchange, functional class, quality of life, and neurohormonal modulation in patients with ischemic chronic heart failure. J Cardiovasc Pharmacol Ther. 2010 Dec;15(4):349–355. doi: 10.1177/1074248410370326
   PubMed Web of Science ®Google Scholar
• Swedberg K, Komajda M, Böhm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010 Sep 11;376(9744):875–885. doi: 10.1016/S0140-6736(10)61198-1
   PubMed Web of Science ®Google Scholar
• Fox K, Komajda M, Ford I, et al. Effect of ivabradine in patients with left-ventricular systolic dysfunction: a pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials. Eur Heart J. 2013 Aug;34(29):2263–2270. doi: 10.1093/eurheartj/eht101
   PubMed Web of Science ®Google Scholar
• Sisakian H, Sargsyan T, Khachatryan A. Effect of selective heart rate reduction through sinus node I(f) current inhibition on severely impaired left ventricular diastolic dysfunction in patients with chronic heart failure. Acta Cardiol. 2016 Jun;71(3):317–322. doi: 10.1080/AC.71.3.3152092
   PubMed Web of Science ®Google Scholar
• Tregubov VG, Kanorsky SG, Pokrovsky VM. Evaluation of the regulatory-adaptive status for prognostication in systolic chronic heart failure [in Russian]. Klin Med (Mosk). 2015;93(11):22–28.
   PubMedGoogle Scholar
• Jamil HA, Gierula J, Paton MF, et al. Chronotropic incompetence does not limit exercise capacity in chronic heart failure. J Am Coll Cardiol. 2016 Apr 26;67(16):1885–1896. doi: 10.1016/j.jacc.2016.02.042
   PubMed Web of Science ®Google Scholar
• Tsutsui H, Momomura SI, Yamashina A, et al. Efficacy and safety of ivabradine in Japanese patients with chronic heart failure: J-SHIFT study. Circ J. 2019 Sep 25;83(10):2049–2060. doi: 10.1253/circj.CJ-19-0227
   PubMed Web of Science ®Google Scholar
• Villacorta AS, Villacorta H, Caldas JA, et al. Effects of heart rate reduction with either pyridostigmine or ivabradine in patients with heart failure: a randomized, double-blind study. J Cardiovasc Pharmacol Ther. 2019 Mar;24(2):139–145. doi: 10.1177/1074248418799364
   PubMed Web of Science ®Google Scholar
• Chang HF, Feng AN, Huang KC et al. Effects of ivabradine on patients with depressed left ventricular ejection fraction after cardiac resynchronization therapy. European Journal of Heart Failure. Conference: Heart Failure 2019 and the World Congress on Acute Heart Failure; Athens Greece: Cardiology ESo, ed. Athens, Greece: European Society of Cardiology: ESC Heart Failure; 2019. p. 408.
   Google Scholar
• Guzman M, Gomez R, Romero SP, et al. Prognosis of heart failure treated with digoxin or with ivabradine: a cohort study in the community. Int J Clin Pract. 2018 Nov;72(11):e13217. doi: 10.1111/ijcp.13217
   PubMed Web of Science ®Google Scholar
• Liao CT, Huang JL, Liang HW, et al. The association between ivabradine and adverse cardiovascular events in acute decompensated HFrEF patients. ESC Heart Fail. 2021 Oct;8(5):4199–4210. doi: 10.1002/ehf2.13536
   PubMed Web of Science ®Google Scholar
• Lopatin YM, Cowie MR, Grebennikova AA, et al. Optimization of heart rate lowering therapy in hospitalized patients with heart failure: insights from the optimize heart failure care program. Int J Cardiol. 2018 Jun 1;260:113–117. doi: 10.1016/j.ijcard.2017.12.093
   PubMed Web of Science ®Google Scholar
• Prathibha V, Mukundan C, Bhagyalekshmi N. Ivabradine alone and in combination with metoprolol reduces the incidence of major adverse cardiac events in patients with heart failure: a prospective study. Natl J Physiol Pharm Pharmacol. 2020;10(5):423–430.
   Google Scholar
• Riccioni G, Masciocco L, Benvenuto A, et al. Ivabradine improves quality of life in subjects with chronic heart failure compared to treatment with β-blockers: results of a multicentric observational APULIA study. Pharmacology. 2013;92(5–6):276–280. doi: 10.1159/000355169
   PubMed Web of Science ®Google Scholar
• Bocchi EA, Rassi S, Guimarães GV. Safety profile and efficacy of ivabradine in heart failure due to Chagas heart disease: a post hoc analysis of the SHIFT trial. ESC Heart Fail. 2018 Jun;5(3):249–256. doi: 10.1002/ehf2.12240
   PubMed Web of Science ®Google Scholar
• Babushkina GV, Khairutdinova GI. Assessment of diastolic function of the left ventricle, intima-media thickness and exercise tolerance in chd patients taking bisoprolol and ivabradine. Russ J Cardiol. 2016;131(3):87–91. doi: 10.15829/1560-4071-2016-3-87-91
   Google Scholar
• Zweerink A, van der Lingen ACJ, Handoko ML, et al. Chronotropic incompetence in chronic heart failure. Circ Heart Fail. 2018 Aug;11(8):e004969. doi: 10.1161/CIRCHEARTFAILURE.118.004969
   PubMed Web of Science ®Google Scholar
• Tatarchenko IP, Pozdniakova NV, Biriuchenko MV, et al. Clinical efficacy of ivabradin and nebivolol addition in combined treatment of ischemic heart disease patients with left ventricular dysfunction [in Russian]. Ter Arkh. 2008;80(9):40–44.
   PubMed Web of Science ®Google Scholar
• Kanorsky SG, Borisenko YV. Comparative evaluation of β-blockers and if-channel inhibitor in patients with chronic heart failure and preserved left ventricular ejection fraction [in Russian]. Kardiologiia. 2016 Feb;56(2):24–29. doi: 10.18565/cardio.2016.2.24-29
   PubMed Web of Science ®Google Scholar
• Sen J, Chung E, McGill D. Tolvaptan for heart failure in chronic kidney disease patients: a systematic review and meta-analysis. Heart Lung Circ. 2018 Aug;27(8):928–939. doi: 10.1016/j.hlc.2017.12.013
   PubMed Web of Science ®Google Scholar
• Bouabdallaoui N, O’Meara E, Bernier V, et al. Beneficial effects of ivabradine in patients with heart failure, low ejection fraction, and heart rate above 77 b.P.m. ESC Heart Fail. 2019 Dec;6(6):1199–1207. doi: 10.1002/ehf2.12513
   PubMed Web of Science ®Google Scholar
• Böhm M, Komajda M, Borer JS, et al. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. Eur J Heart Fail. 2018 Feb;20(2):373–381. doi: 10.1002/ejhf.1021
   PubMed Web of Science ®Google Scholar
• Borer JS, Swedberg K, Komajda M, et al. Efficacy profile of ivabradine in patients with heart failure plus angina pectoris. Cardiol. 2017;136(2):138–144. doi: 10.1159/000449243
   PubMed Web of Science ®Google Scholar
• Hu DY, Huang DJ, Yuan ZY, et al. Efficacy and safety analysis of ivabradine hydrochloride treatment of Chinese patients with chronic heart failure: subgroup analysis of Chinese patients in the SHIFT study [in Chinese]. Zhonghua Xin Xue Guan Bing Za Zhi. 2017 Mar 24;45(3):190–197. doi: 10.3760/cma.j.issn.0253-3758.2017.03.005
   PubMedGoogle Scholar
• Komajda M, Tavazzi L, Francq B, et al. Efficacy and safety of ivabradine in patients with chronic systolic heart failure and diabetes: an analysis from the SHIFT trial. Eur J Heart Fail. 2015 09 17;17(12):1294–1301. doi: 10.1002/ejhf.347
   PubMed Web of Science ®Google Scholar
• Rogers JK, Kielhorn A, Borer JS, et al. Effect of ivabradine on numbers needed to treat for the prevention of recurrent hospitalizations in heart failure patients. Curr Med Res Opin. 2015;31(10):1903–1909. doi: 10.1185/03007995.2015.1080155
   PubMed Web of Science ®Google Scholar
• Komajda M, Böhm M, Borer J, et al. Efficacy and safety of ivabradine in patients with chronic systolic heart failure according to blood pressure level in SHIFT. Eur J Heart Fail. 2014 07 01;16(7):810–816. doi: 10.1002/ejhf.114
   PubMed Web of Science ®Google Scholar
• Voors AA, van Veldhuisen DJ, Robertson M, et al. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. Eur J Heart Fail. 2014 Apr;16(4):426–434. doi: 10.1002/ejhf.59
   PubMed Web of Science ®Google Scholar
• Tavazzi L, Swedberg K, Komajda M, et al. Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: insights from the SHIFT study. Eur J Heart Fail. 2013 11 01;15(11):1296–1303. doi: 10.1093/eurjhf/hft102
   PubMed Web of Science ®Google Scholar
• Reil J-C, Robertson M, Ford I, et al. Impact of left bundle branch block on heart rate and its relationship to treatment with ivabradine in chronic heart failure. Eur J Heart Fail. 2013 05/21; 15;15(9):1044–1052. doi: 10.1093/eurjhf/hft072
   PubMed Web of Science ®Google Scholar
• Komajda M, Böhm M, Borer J, et al. Influence of background treatment with mineralocorticoid receptor antagonists on ivabradine’s effects in patients with chronic heart failure. Eur J Heart Fail. 2013 Jan;15(1):79–84. doi: 10.1093/eurjhf/hfs127
   PubMed Web of Science ®Google Scholar
• Tavazzi L, Swedberg K, Komajda M, et al. Clinical profiles and outcomes in patients with chronic heart failure and chronic obstructive pulmonary disease: an efficacy and safety analysis of SHIFT study. Int J Cardiol. 2013 12 01;170(2):182–188. doi: 10.1016/j.ijcard.2013.10.068
   PubMed Web of Science ®Google Scholar
• Tregubov VG, Kanorskiy SG, Pokrovskiy VM. Regulatory adaptive status in assessment of efficacy of pharmacotherapy and prognostication of complications in functional class III chronic heart failure [in Russian]. Kardiologiia. 2016 Jan;56(1):12–17. doi: 10.18565/cardio.2016.1.12-17
   PubMed Web of Science ®Google Scholar
• Ekman I, Chassany O, Komajda M, et al. Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study. Eur Heart J. 2011 Oct;32(19):2395–2404. doi: 10.1093/eurheartj/ehr343
   PubMed Web of Science ®Google Scholar
• Tardif JC, O’Meara E, Komajda M, et al. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. Eur Heart J. 2011 Oct;32(20):2507–2515. doi: 10.1093/eurheartj/ehr311
   PubMed Web of Science ®Google Scholar
• Pal N, Sivaswamy N, Mahmod M, et al. Effect of selective heart rate slowing in heart failure with preserved ejection fraction. Circulation. 2015 Nov 3;132(18):1719–1725. doi: 10.1161/CIRCULATIONAHA.115.017119
   PubMed Web of Science ®Google Scholar
• Borer JS, Böhm M, Ford I, et al. Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study). Am J Cardiol. 2014;113(3):497–503. 2014/02/01/. doi: 10.1016/j.amjcard.2013.10.033
   PubMed Web of Science ®Google Scholar
• Lee YH, Lin PL, Chiou WR, et al. Combination of ivabradine and sacubitril/valsartan in patients with heart failure and reduced ejection fraction. ESC Heart Fail. 2021 Apr;8(2):1204–1215. doi: 10.1002/ehf2.13182
   PubMed Web of Science ®Google Scholar
• Mircheva L. Benefits of early administration of ivabradine in stabilized patients hospitalized due to worsening heart failure: insights from the optimize heart failure care program. Heart failure. Athens: European Society of Cardiology; 2019.
   Google Scholar
• Hartmann C, Bosch NL, de Aragão Miguita L, et al. The effect of ivabradine therapy on heart failure patients with reduced ejection fraction: a systematic review and meta-analysis. Int J Clin Pharm. 2018 Dec;40(6):1443–1453. doi: 10.1007/s11096-018-0715-8
   PubMed Web of Science ®Google Scholar
• Maagaard M, Nielsen EE, Sethi NJ, et al. Ivabradine added to usual care in patients with heart failure: a systematic review with meta-analysis and trial sequential analysis. BMJ Evid Based Med. 2022 Aug;27(4):224–234. doi: 10.1136/bmjebm-2021-111724
   PubMedGoogle Scholar
• Benstoem C, Kalvelage C, Breuer T, et al. Ivabradine as adjuvant treatment for chronic heart failure. Cochrane Database Syst Rev. 2020 Nov 4;11(11):Cd013004. doi: 10.1002/14651858.CD013004.pub2
   PubMedGoogle Scholar
• Ye F, Wang X, Wu S, et al. Sustained-release ivabradine hemisulfate in patients with systolic heart failure. J Am Coll Cardiol. 2022 Aug 9;80(6):584–594. doi: 10.1016/j.jacc.2022.05.027
   PubMed Web of Science ®Google Scholar
• Dogheim GM, Khairat I, Omran GA, et al. Clinical comparative study assessing the effect of ivabradine on neopterin and NT-Pro BNP against standard treatment in chronic heart failure patients. Eur J Clin Pharmacol. 2022 Jun;78(6):943–954. doi: 10.1007/s00228-022-03290-6
   PubMed Web of Science ®Google Scholar
• Al-Balushi S, Alam MF, Abid AR, et al. The effect of ivabradine on hospitalization of heart failure patients: a retrospective cohort study. Heart Views. 2021 Jul-Sep;22(3):165–173. doi: 10.4103/HEARTVIEWS.HEARTVIEWS_23_20
   PubMedGoogle Scholar
• Lin YS, Jan JY, Chang JJ, et al. Ivabradine in heart failure patients with reduced ejection fraction and history of paroxysmal atrial fibrillation. ESC Heart Fail. 2022 Aug;9(4):2548–2557. doi: 10.1002/ehf2.13966
   PubMed Web of Science ®Google Scholar
• Yang TY, Tsai MS, Jan JY, et al. Early administration of ivabradine in patients admitted for acute decompensated heart failure. Front Cardiovasc Med. 2022;9:1036418. doi: 10.3389/fcvm.2022.1036418
   PubMed Web of Science ®Google Scholar